Market Access News | pharmaphorum

News

NHS England improves offer to Vertex over CF drugs

NHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to give patients access to cystic fibrosis (CF) medicines.

News

Lilly moves Crohn's drug into phase 3, faces safety setback ...

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce

News

After years of delays, NICE backs Celgene's Revlimid in firs...

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with

News

Gilead faces lawsuit over HIV drug pricing

Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.

News

NHS chief hails SMA drug deal - and was that a swipe at Vert...

Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s super-expensive new drug Spinraza after the manufacturer struck a deal wit

News

Teva vows to fight price-fixing lawsuit

Teva has said it will defend itself against a lawsuit raised by 44 US states that alleges the company was the ringleader in an illegal price-fixing scheme involving 19 other generic compani

NHS England improves offer to Vertex over CF drugs

Lilly moves Crohn's drug into phase 3, faces safety setback ...

After years of delays, NICE backs Celgene's Revlimid in firs...

Gilead faces lawsuit over HIV drug pricing

NHS chief hails SMA drug deal - and was that a swipe at Vert...

Teva vows to fight price-fixing lawsuit

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

How to meet your physicians where they are online

News

Editor's Picks